In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.
Did you know that your browser is out of date? To get the best experience using our website we recommend that you upgrade to a newer version. Learn more.

Pocket Guidelines on Cancer Treatment and Cardiovascular Toxicity

ESC Pocket Guidelines

Valvular, Myocardial, Pericardial, Pulmonary, Congenital Heart Disease

Chairperson and Co-Chaiperson:  Jose Luis Zamorano and Patrizio Lancelotti

Published in: 2016

Order Pocket Guidelines


Cardiovascular complications of cancer therapy: pathophysiology and management

  • Myocardial dysfunction and heart failure....
  • Coronary artery disease
  • Valvular disease
  •  Arrhythmias
  • Systemic hypertension
  • Thromboembolic disease
  • Peripheral vascular disease and stroke.
  • Pulmonary hypertension
  • Other cardiovascular complications of cancer treatment
  • Cardiovascular complications of cancer treatment in special populations

Strategies for prevention and attenuation of cardiovascular complications of cancer therapy

  • Treatment options to prevent or recover from cancer therapy-induced myocardial dysfunction
  • Prevention of thromboembolic events
  • Strategies for attenuation of complications related to use of specific agents

Long-term surveillance programmes for cancer survivors.

  • Myocardial dysfunction
  • Vascular disease
  • Valvular disease

Future perspectives and research directions